Pancani Elisabetta

Research Fellow
Office telephone : 
+39 051 639 9819
Isof 4
Office number: 
Research Unit: 
Research Fellows

▪ Machelart A., Salzano G., Li X., Demars A., Debrie A.-S., Menendez-Miranda M., Pancani E. et al. “Intrinsic Antibacterial Activity of Nanoparticles Made of β-Cyclodextrins Potentiates Their Effect as Drug Nanocarriers against Tuberculosis.” ACSNano 1343992-4007 (2019). doi:10.1021/acsnano.8b07902.

▪ Mathurin J.*, Pancani E.* et al. “How to unravel the chemical structure and component localization of individual drug-loaded polymeric nanoparticles by using tapping AFM-IR.” Analyst 143, 5940-5949 (2018). doi:10.1039/C8AN01239C.

Pancani E. et al. “Nanoparticles with high payloads of pipemidic acid, a poorly soluble crystalline drug: drug-initiated polymerization and self-assembly approach.” Acta Pharm. Sin. B 8(3): 420–431 (2018). doi: 10.1016/j.apsb.2018.03.008.

Pancani E. et al. “High resolution label-free detection of biocompatible polymeric nanoparticles in cells.” Part. Part. Syst. Charact. 1700457 (2018). doi:10.1002/ppsc.201700457. (Selected for cover picture:

▪ Costa-Gouveia J.*, Pancani E.* et al. “Combination therapy for tuberculosis treatment: pulmonary administration of ethionamide and booster co-loaded nanoparticles.” Sci. Rep. 7, 5390 (2017). doi: 10.1038/s41598-017-05453-3.

▪ Wankar J., Salzano G., Pancani E. et al. “Efficient loading of ethionamide in cyclodextrin-based carriers offers enhanced solubility and inhibition of drug crystallization.” Int. J Pharm 531(2): 568-576 (2017). doi:10.1016/j.ijpharm.2017.05.041.

▪ Lainé AL, Gravier J, Henry M, Sancey L, Béjaud J, Pancani E. et al. Convetional versus stealth lipid nanoparticles: formulation and in vivo fate prediction through FRET monitoring."J Control Release 188: 1-8 (2014).

* equally contributing first authors